
    
      The study is composed of 2 stages. Stage 1 consists of dose escalation cohorts for
      determining the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2
      consists of 4 tumor type expansion cohorts for expanding the information on clinical safety,
      clinical pharmacokinetics and antitumor activity in HER2 positive patients.
    
  